[go: up one dir, main page]

AR011047A1 - VACCINES TO PREVENT INFECTIONS PRODUCED BY CHLAMYDIA TRACHOMATIS, PROCEDURE TO OBTAIN THEM AND USE OF MUCOSAL ADJUVANTS COMBINED WITH MAJOR LAPROTEIN OF THE CHLAMYDIA TRACHOMATIS DIAPHRAGM IN THE MANUFACTURING - Google Patents

VACCINES TO PREVENT INFECTIONS PRODUCED BY CHLAMYDIA TRACHOMATIS, PROCEDURE TO OBTAIN THEM AND USE OF MUCOSAL ADJUVANTS COMBINED WITH MAJOR LAPROTEIN OF THE CHLAMYDIA TRACHOMATIS DIAPHRAGM IN THE MANUFACTURING

Info

Publication number
AR011047A1
AR011047A1 ARP970106145A ARP970106145A AR011047A1 AR 011047 A1 AR011047 A1 AR 011047A1 AR P970106145 A ARP970106145 A AR P970106145A AR P970106145 A ARP970106145 A AR P970106145A AR 011047 A1 AR011047 A1 AR 011047A1
Authority
AR
Argentina
Prior art keywords
chlamydia trachomatis
vaccines
major
laprotein
diaphragm
Prior art date
Application number
ARP970106145A
Other languages
Spanish (es)
Original Assignee
Smithkline Beecham Biolog
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Biolog filed Critical Smithkline Beecham Biolog
Publication of AR011047A1 publication Critical patent/AR011047A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/118—Chlamydiaceae, e.g. Chlamydia trachomatis or Chlamydia psittaci
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se proporcionan preparaciones de vacuna que comprenden una proteína principal de la membrana externa de Chlamidya, (MOMP) y un adyuvante para lamucosa tal como la toxina del colera o la enterotroxina termolábil. Tales preparaciones proporcionan proteccion contra la infertilidad inducida porChlamydia. También se prepara el uso de dichos adyuvantes en la formulacion de esa clase de vacunas y procedimientos para fabricar las vacunas mencionadas.Vaccine preparations are provided that comprise a major outer membrane protein of Chlamidya, (MOMP) and an adjuvant for the mucosa such as cholera toxin or heat labile enterotroxin. Such preparations provide protection against Chlamydia-induced infertility. The use of such adjuvants in the formulation of that class of vaccines and methods of making the mentioned vaccines are also prepared.

ARP970106145A 1996-12-24 1997-12-23 VACCINES TO PREVENT INFECTIONS PRODUCED BY CHLAMYDIA TRACHOMATIS, PROCEDURE TO OBTAIN THEM AND USE OF MUCOSAL ADJUVANTS COMBINED WITH MAJOR LAPROTEIN OF THE CHLAMYDIA TRACHOMATIS DIAPHRAGM IN THE MANUFACTURING AR011047A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9626864.4A GB9626864D0 (en) 1996-12-24 1996-12-24 Vaccine

Publications (1)

Publication Number Publication Date
AR011047A1 true AR011047A1 (en) 2000-08-02

Family

ID=10805014

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP970106145A AR011047A1 (en) 1996-12-24 1997-12-23 VACCINES TO PREVENT INFECTIONS PRODUCED BY CHLAMYDIA TRACHOMATIS, PROCEDURE TO OBTAIN THEM AND USE OF MUCOSAL ADJUVANTS COMBINED WITH MAJOR LAPROTEIN OF THE CHLAMYDIA TRACHOMATIS DIAPHRAGM IN THE MANUFACTURING

Country Status (9)

Country Link
EP (1) EP0948352A1 (en)
JP (1) JP2001507004A (en)
AR (1) AR011047A1 (en)
AU (1) AU5763998A (en)
CA (1) CA2275896A1 (en)
CO (1) CO4650187A1 (en)
GB (1) GB9626864D0 (en)
WO (1) WO1998028005A1 (en)
ZA (1) ZA9711565B (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1486215A3 (en) * 1997-03-21 2006-04-12 Chiron Corporation Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
US5962636A (en) * 1998-08-12 1999-10-05 Amgen Canada Inc. Peptides capable of modulating inflammatory heart disease
US20020061848A1 (en) 2000-07-20 2002-05-23 Ajay Bhatia Compounds and methods for treatment and diagnosis of chlamydial infection
US7722887B1 (en) * 1999-09-15 2010-05-25 Mogam Biotechnology Research Institute Detoxified mutants of escherichia coli heat-labile enterotoxin
EP1812058B1 (en) * 2004-10-25 2012-06-13 Statens Serum Institut Chlamydia trachomatis antigens for vaccine and diagnostic use
KR20070121814A (en) * 2005-03-31 2007-12-27 글락소스미스클라인 바이오로지칼즈 에스.에이. Vaccines against Chlamydia Infection
US8541007B2 (en) 2005-03-31 2013-09-24 Glaxosmithkline Biologicals S.A. Vaccines against chlamydial infection
EP2576602B1 (en) 2010-05-28 2020-02-12 Spixia Biotechnology AB Chimeric momp antigen, method and use
CA2976243C (en) 2015-02-10 2023-10-31 Ohio State Innovation Foundation Chlamydia-activated b cell platforms and methods thereof
US10835601B2 (en) 2015-11-10 2020-11-17 Ohio State Innovation Foundation Methods and compositions related to accelerated humoral affinity
AR132053A1 (en) 2023-03-02 2025-05-21 Sanofi Pasteur COMPOSITIONS FOR USE IN THE TREATMENT OF CHLAMYDIA

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6019982A (en) * 1994-08-26 2000-02-01 The Administrators Of The Tulane Educational Fund Mutant enterotoxin effective as a non-toxic oral adjuvant
JPH10509325A (en) * 1994-11-17 1998-09-14 マキシム ファーマシューティカルズ，インコーポレイテッド An immunogen that stimulates mucosal immunity
GB9506863D0 (en) * 1995-04-03 1995-05-24 Smithkline Beecham Biolog Vaccines
FR2732605B1 (en) * 1995-04-07 1997-05-16 Pasteur Merieux Serums Vacc COMPOSITION FOR INDUCING MUCOSAL IMMUNE RESPONSE
CN1195297A (en) * 1995-07-07 1998-10-07 奥拉瓦克斯有限公司 Clostridium difficile toxin as a mucosal adjuvant

Also Published As

Publication number Publication date
AU5763998A (en) 1998-07-17
CA2275896A1 (en) 1998-07-02
WO1998028005A1 (en) 1998-07-02
ZA9711565B (en) 1998-08-27
JP2001507004A (en) 2001-05-29
EP0948352A1 (en) 1999-10-13
CO4650187A1 (en) 1998-09-03
GB9626864D0 (en) 1997-02-12

Similar Documents

Publication Publication Date Title
AR011047A1 (en) VACCINES TO PREVENT INFECTIONS PRODUCED BY CHLAMYDIA TRACHOMATIS, PROCEDURE TO OBTAIN THEM AND USE OF MUCOSAL ADJUVANTS COMBINED WITH MAJOR LAPROTEIN OF THE CHLAMYDIA TRACHOMATIS DIAPHRAGM IN THE MANUFACTURING
ES2150982T3 (en) PHARMACEUTICAL COMPOSITION FOR THE TOPIC ADMINISTRATION OF ANTIGENS AND / OR VACCINES TO MAMMALS THROUGH A MUCOUS MEMBRANE.
ES2180758T3 (en) ACCELULAR PERTUSSIS VACCINES AND METHODS OF PREPARATION OF THE SAME.
AR058543A1 (en) NEW COMPOSITION OF VACCINE POTENTIATED WITH A LIPOSOMAL ASSISTANT
AR019026A1 (en) ADJUSTMENT COMPOSITION THAT INCLUDES A SURFACTANT, ADJUSTMENT COMBINATION THAT UNDERSTANDS IT, VACCINE COMPOSITION THAT UNDERSTANDS THEM, USE OF THE DICHOSURFACTANT AND SUCH COMPOSITION TO MANUFACTURE OF VACCINE COMPOSITION, ROUND ROLLING METHOD, COMPONENT USE OF VACCINE
ES2149361T3 (en) LIVING VACCINE MODIFIED AGAINST BRSV, IMPROVED.
PT865297E (en) COMPOSITIONS OF VACCINES FOR INTRANASAL ADMINISTRATION UNDERSTANDING QUITOSAN AND ITS USES
ATE196737T1 (en) ADJUVANTS FOR VACCINES AGAINST RESPIRATORY SYNCITIAL VIRUS
CO2022012819A2 (en) Formulations and uses thereof
ES2136088T3 (en) IMMUNOGENIC COMPOUNDS WITH A MAIN ANTI-CYTOKINE EFFECT, PREPARATION PROCEDURE, PHARMACEUTICAL COMPOSITIONS AND KITS CONTAINING THEM.
MX9702336A (en) Vaccine compositions.
ES2098029T3 (en) HEPATITIS VACCINES CONTAINING 3-O-DESACLATED LIPIDO MONOFOSFORIL.
ATE350057T1 (en) VACCINE COMPOSITION
ES2075325T3 (en) VACCINE SUBUNIT AGAINST ACTINOBACILLUS PLEUROPNEUMONIAE.
AU5162201A (en) Immunostimulant compositions comprising an aminoalkyl glucosaminide phosphate and qs-21
CR20230312A (en) Hiv vaccines and methods of using
DK1259259T3 (en) Mucosal adjuvant formulation
AR011509A1 (en) COMPOSITION OF A VACCINE, INCLUDING ANTIGENS OF DIPHTHERIA, TETANE, AND WHOLE COUGH (PERTUSIS) AND ITS USE FOR THE MANUFACTURE OF A MEDICINE USEFUL AS A VACCINE REINFORCER.
PT1024824E (en) COMPOSITION OF SOLID DISPERSIVAL VACCINE FOR ORAL ADMINISTRATION
AR024213A1 (en) HETEROCHEMERIC PROTEINS AND VACCINES AGAINST PARAMIXOVIRUS.
AR108718A2 (en) COMPOSITION
CO2023010612A2 (en) Recombinant meningococcal b vaccine
WO2024261351A3 (en) Immunologically active saponin fractions and adjuvant formulations
AR010568A1 (en) POLYPEPTIDE, VACCINE COMPOSITION, USE OF POLYPEPTIDE IN THE MANUFACTURE OF A COMPOSITION, AND METHOD TO PRODUCE AN IMMUNO-PROTECTIVE RESPONSE AGAINST HELICOBACTER PYLORI INFECTION
ATE335505T1 (en) SAPONIN INACTIVATED MYCOPLASMA VACCINES